+ 2.03
+ 1.18%

Why Fennec Pharmaceuticals's Stock is Trading Higher Today

April 21, 2021 11:12 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Fennec Pharmaceuticals's Stock Price And Volume Action

Fennec Pharmaceuticals's (NASDAQ:FENC) stock is trading up 7.71% to a price of $6.67. Wednesday the stock has been traded at a volume of 57.39 thousand, about 43.35% of its recent 30-day volume average of 132.38 thousand.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Fennec Pharmaceuticals shares are trading higher after Craig-Hallum initiated coverage on the stock with a Buy rating and a price target of $17 per share.

Further Analysis of Recent Price Action

The 50-day moving average price of Fennec Pharmaceuticals's stock was $7.18 when this article was published. The stock reached a high of $10.67 and a low of $4.8 in the past 52 weeks.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.


Movers Trading Ideas

Related Articles

51 Biggest Movers From Yesterday

Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. read more

42 Stocks Moving in Monday's Pre-Market Session

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 121.7% to $5.83 in pre-market trading after the U.S. FDA issued an emergency use authorization for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. read more

77 Biggest Movers From Yesterday

Gainers Kelly Services, Inc. (NASDAQ: KELYB) shares jumped 118.3% to close at $38.21 on Tuesday. Kelly Services released Q2 earnings last week. read more

58 Stocks Moving In Tuesday's Mid-Day Session

Gainers Pfenex Inc. (NYSE: PFNX) shares climbed 69.5% to $12.91. Ligand Pharmaceuticals Inc. (NASDAQ: LGND) announced plans to acquire Pfenex for $12 per share in cash. read more